Abstract
The degree of tumor load reduction after therapy, which is determined by the degrees of cytoreduction and cytogenetic response, is an important prognostic factor for patients with chronic myelogenous leukemia (CML). Conventional metaphase analysis is considered to be the “gold standard” for evaluating cytogenetic response. The frequency of cytogenetic analysis can be reduced considerably if patients are monitored by molecular methods, such as quantitative Southern blot, fluorescence in situ hybridization (FISH), quantitative western blot, or competitive reverse transcriptase polymerase chain reaction (RT-PCR). Molecular methods can be performed on peripheral blood specimens and are therefore less invasive than cytogenetic analyses of bone marrow metaphases. Furthermore these techniques are applicable to Ph-negative/BCR-AbL-positive cases. Results obtained by Southern blotting, western blotting, and FISH are readily quantifiable but their sensitivity is not generally superior to that of cytogenetic methods. RT-PCR is by far the most sensitive method. Quantitative RT-PCR analysis is the method of choice for monitoring patients after bone marrow transplantation (BMT). Using competitive PCR in patients after BMT, reappearance and/or rising levels of BCR-ABL transcripts can be detected prior to relapse. All complete cytogenetic responders to interferon-α are positive for BCR-ABL transcripts. The level of residual disease spans a range over found orders of magnitude. In both interferon-α-treated patients and patients after BMT a good correlation between BCR-ABL transcript numbers per microgram of RNA and cytogenetic results has been found. Variables in the competitive PCR assay may be controlled for by quantification of transcripts of the normal ABL gene as an internal standard. We suggest a stepwise strategy for diagnosis and follow-up of CML patients employing molecular methods.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Allan NC, Richards SM, Shepherd PC (1995) UK Medical Research Council randomised, multicentre trial of interferon-alpha n 1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council’s Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 345:1392–1397
Bartram CR, Bross Bach U, Schmidt H, Waller HD (1987) Philadelphia-positive chronic myelogenous leukemia with breakpoint 5′ of the breakpoint cluster region but within the bcr gene. Blut 55:505–511
Bentz M, Cabot G, Moos M, Speicher MR, Ganser A, Lichter P, Dohner H (1994) Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization. Blood 83:1922–1928
Cox Froncillo MC, Maffei L, Cantonetti M, Del Poeta G, Lentini R, Bruno A, Masi M, Tribalto M, Amadori S (1996) FISH analysis for CML monitoring? Ann Hematol 73:113–119
Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM (1993) Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82:1929–1936
Cross NCP, Melo JV, Goldman JM (1994 a) An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 8:186–189
Cross NCP, Feng L, Zhang JG, Goldman JM (1994b) Competitive PCR to monitor residual disease after bone marrow transplantation for chronic myeloid leukaemia. In: Borden EC, Goldman JM, Grignani F (eds) Molecular diagnosis and monitoring of leukaemia and lymphoma. Ares-Serono Symposia Publications, pp 119–126
De Klein A, Hagemeijer A, Bartram CR, Houwen R, Hoefsloot L, Carbonell F, Chan L, Barnett M, Greaves M, Kleihauer E et al (1986) bcr rearrangement and translocation of the c-abl oncogene in Philadelphia positive acute lymphoblastic leukemia. Blood 68:1369–1375
Gordon MY, Goldman JM (1996) Cellular and molecular mechanisms in chronic myeloid leukaemia: biology and treatment. Br J Haematol 95:10–20
Grossman A, Silver RT, Szatroswki TP, Gutfriend A, Verma RS, Benn PA, (1991) Densito-metric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemia. Leukemia 5:540–547
Guo JQ, Lian JY, Xian YM, Lee MS, Deisseroth AB, Stass SA, Champlin RE, Talpaz M, Wang JY, Arlinghaus RB (1994) BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy. Blood 83:3629–3637
Guo JQ, Lian J, Glassman A, Talpaz M, Kantarjian H, Deisseroth AB, Arlinghaus RB (1996) Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients. Am J Clin Pathol 106:442–448
Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Loffler H, Hochhaus A, Heinze B et al (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84:4064–4077
Hochhaus A, Lin F, Reiter A, Skladny H, van Rhee F, Shepherd PCA, Allan NC, Hehlmann R, Goldman JM, Cross NCP (1995) Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-α. Br J Haematol 91:126–131
Hochhaus A, Reiter A, Skladny H, Melo JV, Sick C, Berger U, Guo JQ, Arlinghaus RB, Hehlmann R, Goldman JM, Cross NCP (1996a) A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome negative chronic myelogenous leukemia. Blood 88:2236–2240
Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PCA, Allan NC, Hehlmann R, Goldman JM, Cross NCP (1996 b) Quantification of residual disease in chronic myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction. Blood 87:1549–1555
Hook EB (1977) Exclusion of chromosomal mosaicism: tables of 90%, 95%, and 99% confidence limits and comments on use. Am J Hum Genet 29:94–97
Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820–825
Kantarjian HM, Smith TL, O’Brien S, Beran M, Pierce S, Talpaz M, and the Leukemia Service (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 122:254–261
Lin F, van Rhee F, Goldman JM, Cross NCP (1996) Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 87:4473–4478
Melo JV (1996) The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88:2375–2384
Mughal TI, Goldman JM (1995) Chronic myeloid leukaemia: a therapeutic challenge. Ann Oncol 6:637–644
Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawaki S, Tsubaki K et al (1995) A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86:906–916
Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, Meloni G, Saglio G, Salvatore F, Rotoli B (1996) Neutrophilic-chronic myelogenous leukemia (CML-N): a distinct disease with a specific marker (BCR-ABL with c3a2 junction). Blood 88:2410–2414
Potter MN, Cross NCP, van Dongen JJ, Saglio G, Oakhill A, Bartram CR, Goldman JM (1993) Molecular evidence of minimal residual disease after treatment for leukaemia and lymphoma: an updated meeting report and review. Leukemia 7:1302–1314
Reiter A, Skladny H, Hochhaus A, Schultheis B, Bartram CR, Heimpel H, Hehlmann R (1995) Comparison between cytogenetics and quantitative Southern blot analysis for monitoring interferon α treatment CML-patients (Abstr). Blood 86 Suppl 1:527a
Reiter A, Skladny H, Hochhaus A, Seifarth W, Bartram CR, Heimpel H, Cross NCP, Hehlmann R (1997) Quantitative Southern blot for monitoring CML patients on therapy. Br J Haematol 97:86–93
Saglio G, Guerrasio A, Rosso C, Zaccaria A, Tassinari A, Serra A, Rege Cambrin G, Mazza U, Gavosto F (1990) New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 76:1819–1824
Van Rhee F, Lin F, Cullis JO, Spencer A, Cross NCP, Chase A, Garicochea B, Bungey J, Barrett J, Goldman JM (1994) Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 83:3377–3383
Verschraegen CF, Talpaz M, Hirsch Ginsberg CF, Pherwani R, Rios MB, Stass SA, Kantarjian HM (1995) Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosme-positive chronic myeloid leukemia. Blood 85:2705–2710
Westbrook CA (1996) Debate round table: Monitoring of residual disease in chronic myelogenous leukemia: methodological approaches and clinical aspects. Comments. Leukemia 10:905–906
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Hochhaus, A., Reiter, A., Skladny, H., Reichert, A., Saußele, S., Hehlmann, R. (1998). Molecular Monitoring of Residual Disease in Chronic Myelogenous Leukemia Patients After Therapy. In: Advances in Hematopoietic Stem Cell Transplantation and Molecular Therapy. Recent Results in Cancer Research, vol 144. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-46836-0_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-46836-0_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-46838-4
Online ISBN: 978-3-642-46836-0
eBook Packages: Springer Book Archive